Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TAC chemotherapy with short-course radiotherapy and toripalimab for HR-positive/HER2-negative breast cancer
ChiCTR2600135543Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Oct 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of toripalimab, docetaxel, doxorubicin and cyclophosphamide in breast cancer (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Pathological complete response. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
toripalimabdocetaxeldoxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600135543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135543.